Arbutus Biopharma Corporation
Arbutus Biopharma Corporation (ABUS) Stock Competitors & Peer Comparison
See (ABUS) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ABUS | $4.35 | -2.03% | 859.3M | 5.24 | $0.83 | N/A |
| NVO | $44.96 | +1.28% | 199.8B | 10.53 | $4.27 | +4.03% |
| VRTX | $434.52 | +0.23% | 110.3B | 25.82 | $16.83 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $638.88 | -0.58% | 65.8B | 15.61 | $40.93 | +0.57% |
| ARGX | $806.46 | -1.20% | 49.9B | 35.81 | $22.52 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $297.45 | -1.02% | 39.7B | 74.92 | $3.97 | N/A |
| RVMD | $151.56 | -1.41% | 32.2B | -21.31 | -$7.11 | N/A |
| UTHR | $568.43 | +0.45% | 24.1B | 21.00 | $27.07 | N/A |
Stock Comparison
ABUS vs NVO Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, NVO has a market cap of 199.8B. Regarding current trading prices, ABUS is priced at $4.35, while NVO trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas NVO's P/E ratio is 10.53. In terms of profitability, ABUS's ROE is +1.29%, compared to NVO's ROE of +0.66%. Regarding short-term risk, ABUS is more volatile compared to NVO. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check NVO's competition here
ABUS vs VRTX Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, VRTX has a market cap of 110.3B. Regarding current trading prices, ABUS is priced at $4.35, while VRTX trades at $434.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas VRTX's P/E ratio is 25.82. In terms of profitability, ABUS's ROE is +1.29%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, ABUS is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check VRTX's competition here
ABUS vs VRNA Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ABUS is priced at $4.35, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ABUS's ROE is +1.29%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, ABUS is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check VRNA's competition here
ABUS vs REGN Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, REGN has a market cap of 65.8B. Regarding current trading prices, ABUS is priced at $4.35, while REGN trades at $638.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas REGN's P/E ratio is 15.61. In terms of profitability, ABUS's ROE is +1.29%, compared to REGN's ROE of +0.14%. Regarding short-term risk, ABUS is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check REGN's competition here
ABUS vs ARGX Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, ARGX has a market cap of 49.9B. Regarding current trading prices, ABUS is priced at $4.35, while ARGX trades at $806.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas ARGX's P/E ratio is 35.81. In terms of profitability, ABUS's ROE is +1.29%, compared to ARGX's ROE of +0.26%. Regarding short-term risk, ABUS is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check ARGX's competition here
ABUS vs SGEN Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ABUS is priced at $4.35, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ABUS's ROE is +1.29%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ABUS is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check SGEN's competition here
ABUS vs ALNY Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, ALNY has a market cap of 39.7B. Regarding current trading prices, ABUS is priced at $4.35, while ALNY trades at $297.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas ALNY's P/E ratio is 74.92. In terms of profitability, ABUS's ROE is +1.29%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, ABUS is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check ALNY's competition here
ABUS vs RVMD Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, RVMD has a market cap of 32.2B. Regarding current trading prices, ABUS is priced at $4.35, while RVMD trades at $151.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas RVMD's P/E ratio is -21.31. In terms of profitability, ABUS's ROE is +1.29%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, ABUS is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check RVMD's competition here
ABUS vs UTHR Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, UTHR has a market cap of 24.1B. Regarding current trading prices, ABUS is priced at $4.35, while UTHR trades at $568.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas UTHR's P/E ratio is 21.00. In terms of profitability, ABUS's ROE is +1.29%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, ABUS is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check UTHR's competition here
ABUS vs RPRX Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, RPRX has a market cap of 23.4B. Regarding current trading prices, ABUS is priced at $4.35, while RPRX trades at $54.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas RPRX's P/E ratio is 28.69. In terms of profitability, ABUS's ROE is +1.29%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, ABUS is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check RPRX's competition here
ABUS vs BNTX Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, BNTX has a market cap of 23.3B. Regarding current trading prices, ABUS is priced at $4.35, while BNTX trades at $92.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas BNTX's P/E ratio is -15.59. In terms of profitability, ABUS's ROE is +1.29%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, ABUS is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check BNTX's competition here
ABUS vs INSM Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, INSM has a market cap of 23B. Regarding current trading prices, ABUS is priced at $4.35, while INSM trades at $106.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas INSM's P/E ratio is -18.44. In terms of profitability, ABUS's ROE is +1.29%, compared to INSM's ROE of -1.30%. Regarding short-term risk, ABUS is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check INSM's competition here
ABUS vs ROIV Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, ROIV has a market cap of 21.6B. Regarding current trading prices, ABUS is priced at $4.35, while ROIV trades at $29.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas ROIV's P/E ratio is -55.51. In terms of profitability, ABUS's ROE is +1.29%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, ABUS is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check ROIV's competition here
ABUS vs BGNE Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ABUS is priced at $4.35, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ABUS's ROE is +1.29%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, ABUS is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check BGNE's competition here
ABUS vs INCY Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, INCY has a market cap of 19.4B. Regarding current trading prices, ABUS is priced at $4.35, while INCY trades at $97.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas INCY's P/E ratio is 13.72. In terms of profitability, ABUS's ROE is +1.29%, compared to INCY's ROE of +0.29%. Regarding short-term risk, ABUS is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check INCY's competition here
ABUS vs DNA-WT Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ABUS is priced at $4.35, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ABUS's ROE is +1.29%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, ABUS is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for ABUS.Check DNA-WT's competition here
ABUS vs MRNA Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, MRNA has a market cap of 18.6B. Regarding current trading prices, ABUS is priced at $4.35, while MRNA trades at $46.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas MRNA's P/E ratio is -5.76. In terms of profitability, ABUS's ROE is +1.29%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, ABUS is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check MRNA's competition here
ABUS vs GMAB Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, GMAB has a market cap of 16.5B. Regarding current trading prices, ABUS is priced at $4.35, while GMAB trades at $26.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas GMAB's P/E ratio is 20.51. In terms of profitability, ABUS's ROE is +1.29%, compared to GMAB's ROE of +0.21%. Regarding short-term risk, ABUS is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check GMAB's competition here
ABUS vs NBIX Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, NBIX has a market cap of 15.8B. Regarding current trading prices, ABUS is priced at $4.35, while NBIX trades at $156.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas NBIX's P/E ratio is 24.11. In terms of profitability, ABUS's ROE is +1.29%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, ABUS is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check NBIX's competition here
ABUS vs ASND Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, ASND has a market cap of 15.3B. Regarding current trading prices, ABUS is priced at $4.35, while ASND trades at $247.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas ASND's P/E ratio is 28.14. In terms of profitability, ABUS's ROE is +1.29%, compared to ASND's ROE of -56.42%. Regarding short-term risk, ABUS is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check ASND's competition here
ABUS vs JAZZ Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, JAZZ has a market cap of 15B. Regarding current trading prices, ABUS is priced at $4.35, while JAZZ trades at $239.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas JAZZ's P/E ratio is 1998.58. In terms of profitability, ABUS's ROE is +1.29%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, ABUS is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check JAZZ's competition here
ABUS vs BBIO Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, BBIO has a market cap of 13.5B. Regarding current trading prices, ABUS is priced at $4.35, while BBIO trades at $69.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas BBIO's P/E ratio is -18.48. In terms of profitability, ABUS's ROE is +1.29%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, ABUS is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for ABUS.Check BBIO's competition here
ABUS vs SMMT Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, SMMT has a market cap of 12.9B. Regarding current trading prices, ABUS is priced at $4.35, while SMMT trades at $16.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas SMMT's P/E ratio is -10.46. In terms of profitability, ABUS's ROE is +1.29%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, ABUS is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for ABUS.Check SMMT's competition here
ABUS vs EXEL Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, EXEL has a market cap of 12.6B. Regarding current trading prices, ABUS is priced at $4.35, while EXEL trades at $50.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas EXEL's P/E ratio is 16.61. In terms of profitability, ABUS's ROE is +1.29%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, ABUS is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check EXEL's competition here
ABUS vs KRTX Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ABUS is priced at $4.35, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ABUS's ROE is +1.29%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ABUS is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check KRTX's competition here
ABUS vs IONS Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, IONS has a market cap of 12.5B. Regarding current trading prices, ABUS is priced at $4.35, while IONS trades at $75.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas IONS's P/E ratio is -37.59. In terms of profitability, ABUS's ROE is +1.29%, compared to IONS's ROE of -0.59%. Regarding short-term risk, ABUS is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check IONS's competition here
ABUS vs AXSM Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, AXSM has a market cap of 12.1B. Regarding current trading prices, ABUS is priced at $4.35, while AXSM trades at $235.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas AXSM's P/E ratio is -63.43. In terms of profitability, ABUS's ROE is +1.29%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, ABUS is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check AXSM's competition here
ABUS vs MDGL Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, MDGL has a market cap of 11.9B. Regarding current trading prices, ABUS is priced at $4.35, while MDGL trades at $517.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas MDGL's P/E ratio is -38.32. In terms of profitability, ABUS's ROE is +1.29%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, ABUS is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check MDGL's competition here
ABUS vs RNAM Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ABUS is priced at $4.35, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ABUS's ROE is +1.29%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, ABUS is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check RNAM's competition here
ABUS vs ARWR Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, ARWR has a market cap of 10.6B. Regarding current trading prices, ABUS is priced at $4.35, while ARWR trades at $74.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas ARWR's P/E ratio is -33.02. In terms of profitability, ABUS's ROE is +1.29%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, ABUS is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check ARWR's competition here
ABUS vs BMRN Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, BMRN has a market cap of 10.5B. Regarding current trading prices, ABUS is priced at $4.35, while BMRN trades at $54.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas BMRN's P/E ratio is 38.91. In terms of profitability, ABUS's ROE is +1.29%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, ABUS is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check BMRN's competition here
ABUS vs CYTK Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, CYTK has a market cap of 9.6B. Regarding current trading prices, ABUS is priced at $4.35, while CYTK trades at $76.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas CYTK's P/E ratio is -11.23. In terms of profitability, ABUS's ROE is +1.29%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, ABUS is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check CYTK's competition here
ABUS vs RXDX Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ABUS is priced at $4.35, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ABUS's ROE is +1.29%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ABUS is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check RXDX's competition here
ABUS vs KRYS Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, KRYS has a market cap of 8.8B. Regarding current trading prices, ABUS is priced at $4.35, while KRYS trades at $299.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas KRYS's P/E ratio is 40.14. In terms of profitability, ABUS's ROE is +1.29%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ABUS is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check KRYS's competition here
ABUS vs IMGN Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ABUS is priced at $4.35, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ABUS's ROE is +1.29%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ABUS is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check IMGN's competition here
ABUS vs BPMC Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ABUS is priced at $4.35, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ABUS's ROE is +1.29%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, ABUS is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check BPMC's competition here
ABUS vs CERE Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ABUS is priced at $4.35, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas CERE's P/E ratio is -16.47. In terms of profitability, ABUS's ROE is +1.29%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ABUS is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check CERE's competition here
ABUS vs HALO Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, HALO has a market cap of 8.1B. Regarding current trading prices, ABUS is priced at $4.35, while HALO trades at $68.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas HALO's P/E ratio is 23.97. In terms of profitability, ABUS's ROE is +1.29%, compared to HALO's ROE of +1.26%. Regarding short-term risk, ABUS is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check HALO's competition here
ABUS vs ABVX Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, ABVX has a market cap of 8B. Regarding current trading prices, ABUS is priced at $4.35, while ABVX trades at $121.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas ABVX's P/E ratio is -21.75. In terms of profitability, ABUS's ROE is +1.29%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, ABUS is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for ABUS.Check ABVX's competition here
ABUS vs IBRX Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, IBRX has a market cap of 7.6B. Regarding current trading prices, ABUS is priced at $4.35, while IBRX trades at $7.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas IBRX's P/E ratio is -8.49. In terms of profitability, ABUS's ROE is +1.29%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, ABUS is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for ABUS.Check IBRX's competition here
ABUS vs TECH Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, TECH has a market cap of 7.5B. Regarding current trading prices, ABUS is priced at $4.35, while TECH trades at $48.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas TECH's P/E ratio is 68.87. In terms of profitability, ABUS's ROE is +1.29%, compared to TECH's ROE of +0.05%. Regarding short-term risk, ABUS is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check TECH's competition here
ABUS vs NUVL Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, NUVL has a market cap of 7.5B. Regarding current trading prices, ABUS is priced at $4.35, while NUVL trades at $102.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas NUVL's P/E ratio is -16.85. In terms of profitability, ABUS's ROE is +1.29%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, ABUS is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check NUVL's competition here
ABUS vs MTSR Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ABUS is priced at $4.35, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ABUS's ROE is +1.29%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, ABUS is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check MTSR's competition here
ABUS vs PRAX Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, PRAX has a market cap of 7.3B. Regarding current trading prices, ABUS is priced at $4.35, while PRAX trades at $343.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas PRAX's P/E ratio is -25.69. In terms of profitability, ABUS's ROE is +1.29%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, ABUS is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check PRAX's competition here
ABUS vs IMVT Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, IMVT has a market cap of 7B. Regarding current trading prices, ABUS is priced at $4.35, while IMVT trades at $34.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas IMVT's P/E ratio is -12.33. In terms of profitability, ABUS's ROE is +1.29%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, ABUS is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check IMVT's competition here
ABUS vs PCVX Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, PCVX has a market cap of 6.8B. Regarding current trading prices, ABUS is priced at $4.35, while PCVX trades at $47.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas PCVX's P/E ratio is -6.87. In terms of profitability, ABUS's ROE is +1.29%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, ABUS is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check PCVX's competition here
ABUS vs MRUS Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ABUS is priced at $4.35, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ABUS's ROE is +1.29%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, ABUS is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check MRUS's competition here
ABUS vs CELC Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, CELC has a market cap of 6.7B. Regarding current trading prices, ABUS is priced at $4.35, while CELC trades at $138.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas CELC's P/E ratio is -35.44. In terms of profitability, ABUS's ROE is +1.29%, compared to CELC's ROE of -2.45%. Regarding short-term risk, ABUS is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for ABUS.Check CELC's competition here
ABUS vs ACLX Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ABUS is priced at $4.35, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas ACLX's P/E ratio is -28.27. In terms of profitability, ABUS's ROE is +1.29%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, ABUS is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check ACLX's competition here
ABUS vs RETA Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ABUS is priced at $4.35, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas RETA's P/E ratio is -66.29. In terms of profitability, ABUS's ROE is +1.29%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ABUS is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check RETA's competition here
ABUS vs KYMR Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, KYMR has a market cap of 6.5B. Regarding current trading prices, ABUS is priced at $4.35, while KYMR trades at $78.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas KYMR's P/E ratio is -22.04. In terms of profitability, ABUS's ROE is +1.29%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, ABUS is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check KYMR's competition here
ABUS vs CORT Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, CORT has a market cap of 6.5B. Regarding current trading prices, ABUS is priced at $4.35, while CORT trades at $60.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas CORT's P/E ratio is 172.06. In terms of profitability, ABUS's ROE is +1.29%, compared to CORT's ROE of +0.08%. Regarding short-term risk, ABUS is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check CORT's competition here
ABUS vs PTGX Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, PTGX has a market cap of 6.4B. Regarding current trading prices, ABUS is priced at $4.35, while PTGX trades at $99.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas PTGX's P/E ratio is -54.80. In terms of profitability, ABUS's ROE is +1.29%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, ABUS is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check PTGX's competition here
ABUS vs CNTA Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, CNTA has a market cap of 6.2B. Regarding current trading prices, ABUS is priced at $4.35, while CNTA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas CNTA's P/E ratio is -22.33. In terms of profitability, ABUS's ROE is +1.29%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, ABUS is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check CNTA's competition here
ABUS vs ALKS Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, ALKS has a market cap of 6.1B. Regarding current trading prices, ABUS is priced at $4.35, while ALKS trades at $36.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas ALKS's P/E ratio is 40.89. In terms of profitability, ABUS's ROE is +1.29%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, ABUS is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check ALKS's competition here
ABUS vs RYTM Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, RYTM has a market cap of 6B. Regarding current trading prices, ABUS is priced at $4.35, while RYTM trades at $87.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas RYTM's P/E ratio is -28.05. In terms of profitability, ABUS's ROE is +1.29%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, ABUS is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check RYTM's competition here
ABUS vs TGTX Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, TGTX has a market cap of 6B. Regarding current trading prices, ABUS is priced at $4.35, while TGTX trades at $38.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas TGTX's P/E ratio is 13.59. In terms of profitability, ABUS's ROE is +1.29%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, ABUS is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check TGTX's competition here
ABUS vs SRRK Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, SRRK has a market cap of 5.8B. Regarding current trading prices, ABUS is priced at $4.35, while SRRK trades at $48.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas SRRK's P/E ratio is -13.94. In terms of profitability, ABUS's ROE is +1.29%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, ABUS is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check SRRK's competition here
ABUS vs PTCT Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, PTCT has a market cap of 5.7B. Regarding current trading prices, ABUS is priced at $4.35, while PTCT trades at $68.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas PTCT's P/E ratio is -27.09. In terms of profitability, ABUS's ROE is +1.29%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, ABUS is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check PTCT's competition here
ABUS vs CGON Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, CGON has a market cap of 5.7B. Regarding current trading prices, ABUS is priced at $4.35, while CGON trades at $64.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas CGON's P/E ratio is -27.46. In terms of profitability, ABUS's ROE is +1.29%, compared to CGON's ROE of -0.23%. Regarding short-term risk, ABUS is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check CGON's competition here
ABUS vs CDTX Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ABUS is priced at $4.35, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ABUS's ROE is +1.29%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, ABUS is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check CDTX's competition here
ABUS vs COGT Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, COGT has a market cap of 5.6B. Regarding current trading prices, ABUS is priced at $4.35, while COGT trades at $32.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas COGT's P/E ratio is -15.06. In terms of profitability, ABUS's ROE is +1.29%, compared to COGT's ROE of -0.83%. Regarding short-term risk, ABUS is less volatile compared to COGT. This indicates potentially lower risk in terms of short-term price fluctuations for ABUS.Check COGT's competition here
ABUS vs ABCM Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ABUS is priced at $4.35, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ABUS's ROE is +1.29%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ABUS is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check ABCM's competition here
ABUS vs ISEE Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ABUS is priced at $4.35, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ABUS's ROE is +1.29%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ABUS is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check ISEE's competition here
ABUS vs BLTE Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, BLTE has a market cap of 5.5B. Regarding current trading prices, ABUS is priced at $4.35, while BLTE trades at $137.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas BLTE's P/E ratio is -54.06. In terms of profitability, ABUS's ROE is +1.29%, compared to BLTE's ROE of -0.27%. Regarding short-term risk, ABUS is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for ABUS.Check BLTE's competition here
ABUS vs LEGN Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, LEGN has a market cap of 5.4B. Regarding current trading prices, ABUS is priced at $4.35, while LEGN trades at $29.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas LEGN's P/E ratio is -21.28. In terms of profitability, ABUS's ROE is +1.29%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, ABUS is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for ABUS.Check LEGN's competition here
ABUS vs LQDA Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, LQDA has a market cap of 5.4B. Regarding current trading prices, ABUS is priced at $4.35, while LQDA trades at $60.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas LQDA's P/E ratio is 358.71. In terms of profitability, ABUS's ROE is +1.29%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, ABUS is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check LQDA's competition here
ABUS vs APLS Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, ABUS is priced at $4.35, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas APLS's P/E ratio is 38.35. In terms of profitability, ABUS's ROE is +1.29%, compared to APLS's ROE of +0.40%. Regarding short-term risk, ABUS is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check APLS's competition here
ABUS vs FBIOX Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, FBIOX has a market cap of 5.2B. Regarding current trading prices, ABUS is priced at $4.35, while FBIOX trades at $25.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas FBIOX's P/E ratio is N/A. In terms of profitability, ABUS's ROE is +1.29%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, ABUS is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check FBIOX's competition here
ABUS vs APGE Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, APGE has a market cap of 5B. Regarding current trading prices, ABUS is priced at $4.35, while APGE trades at $81.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas APGE's P/E ratio is -18.74. In terms of profitability, ABUS's ROE is +1.29%, compared to APGE's ROE of -0.33%. Regarding short-term risk, ABUS is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check APGE's competition here
ABUS vs MIRM Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, MIRM has a market cap of 5B. Regarding current trading prices, ABUS is priced at $4.35, while MIRM trades at $98.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas MIRM's P/E ratio is -7.25. In terms of profitability, ABUS's ROE is +1.29%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, ABUS is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check MIRM's competition here
ABUS vs CRSP Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, CRSP has a market cap of 4.9B. Regarding current trading prices, ABUS is priced at $4.35, while CRSP trades at $50.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas CRSP's P/E ratio is -8.16. In terms of profitability, ABUS's ROE is +1.29%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, ABUS is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check CRSP's competition here
ABUS vs TERN Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, ABUS is priced at $4.35, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas TERN's P/E ratio is -51.41. In terms of profitability, ABUS's ROE is +1.29%, compared to TERN's ROE of -0.20%. Regarding short-term risk, ABUS is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check TERN's competition here
ABUS vs LGND Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, LGND has a market cap of 4.6B. Regarding current trading prices, ABUS is priced at $4.35, while LGND trades at $229.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas LGND's P/E ratio is 29.90. In terms of profitability, ABUS's ROE is +1.29%, compared to LGND's ROE of +0.16%. Regarding short-term risk, ABUS is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check LGND's competition here
ABUS vs FOLD Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ABUS is priced at $4.35, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas FOLD's P/E ratio is -161.00. In terms of profitability, ABUS's ROE is +1.29%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, ABUS is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check FOLD's competition here
ABUS vs AKRO Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ABUS is priced at $4.35, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ABUS's ROE is +1.29%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, ABUS is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check AKRO's competition here
ABUS vs SYRE Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, SYRE has a market cap of 4.5B. Regarding current trading prices, ABUS is priced at $4.35, while SYRE trades at $74.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas SYRE's P/E ratio is -34.91. In terms of profitability, ABUS's ROE is +1.29%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, ABUS is more volatile compared to SYRE. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check SYRE's competition here
ABUS vs ALPN Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ABUS is priced at $4.35, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ABUS's ROE is +1.29%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ABUS is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check ALPN's competition here
ABUS vs CAI Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, CAI has a market cap of 4.4B. Regarding current trading prices, ABUS is priced at $4.35, while CAI trades at $15.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas CAI's P/E ratio is -5.63. In terms of profitability, ABUS's ROE is +1.29%, compared to CAI's ROE of +0.06%. Regarding short-term risk, ABUS is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for ABUS.Check CAI's competition here
ABUS vs XENE Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, XENE has a market cap of 4.3B. Regarding current trading prices, ABUS is priced at $4.35, while XENE trades at $54.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas XENE's P/E ratio is -11.53. In terms of profitability, ABUS's ROE is +1.29%, compared to XENE's ROE of -0.49%. Regarding short-term risk, ABUS is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check XENE's competition here
ABUS vs MANE Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, MANE has a market cap of 4.2B. Regarding current trading prices, ABUS is priced at $4.35, while MANE trades at $101.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas MANE's P/E ratio is -38.43. In terms of profitability, ABUS's ROE is +1.29%, compared to MANE's ROE of -0.95%. Regarding short-term risk, ABUS is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for ABUS.Check MANE's competition here
ABUS vs OPT Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ABUS is priced at $4.35, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas OPT's P/E ratio is -1.52. In terms of profitability, ABUS's ROE is +1.29%, compared to OPT's ROE of +0.88%. Regarding short-term risk, ABUS is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check OPT's competition here
ABUS vs NAMS Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, NAMS has a market cap of 4.1B. Regarding current trading prices, ABUS is priced at $4.35, while NAMS trades at $35.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas NAMS's P/E ratio is -19.91. In terms of profitability, ABUS's ROE is +1.29%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, ABUS is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for ABUS.Check NAMS's competition here
ABUS vs TVTX Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, TVTX has a market cap of 4.1B. Regarding current trading prices, ABUS is priced at $4.35, while TVTX trades at $44.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas TVTX's P/E ratio is -87.12. In terms of profitability, ABUS's ROE is +1.29%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, ABUS is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check TVTX's competition here
ABUS vs MRTX Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ABUS is priced at $4.35, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ABUS's ROE is +1.29%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ABUS is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check MRTX's competition here
ABUS vs KNSA Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, KNSA has a market cap of 4B. Regarding current trading prices, ABUS is priced at $4.35, while KNSA trades at $53.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas KNSA's P/E ratio is 58.51. In terms of profitability, ABUS's ROE is +1.29%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, ABUS is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check KNSA's competition here
ABUS vs CRNX Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, CRNX has a market cap of 3.9B. Regarding current trading prices, ABUS is priced at $4.35, while CRNX trades at $36.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas CRNX's P/E ratio is -7.16. In terms of profitability, ABUS's ROE is +1.29%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, ABUS is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check CRNX's competition here
ABUS vs CPRX Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, ABUS is priced at $4.35, while CPRX trades at $31.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas CPRX's P/E ratio is 18.07. In terms of profitability, ABUS's ROE is +1.29%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ABUS is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check CPRX's competition here
ABUS vs RYZB Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ABUS is priced at $4.35, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ABUS's ROE is +1.29%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ABUS is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check RYZB's competition here
ABUS vs CBAY Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ABUS is priced at $4.35, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ABUS's ROE is +1.29%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ABUS is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check CBAY's competition here
ABUS vs ACAD Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, ACAD has a market cap of 3.6B. Regarding current trading prices, ABUS is priced at $4.35, while ACAD trades at $21.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas ACAD's P/E ratio is 9.55. In terms of profitability, ABUS's ROE is +1.29%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, ABUS is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check ACAD's competition here
ABUS vs DNTH Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, DNTH has a market cap of 3.6B. Regarding current trading prices, ABUS is priced at $4.35, while DNTH trades at $86.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas DNTH's P/E ratio is -20.44. In terms of profitability, ABUS's ROE is +1.29%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, ABUS is less volatile compared to DNTH. This indicates potentially lower risk in terms of short-term price fluctuations for ABUS.Check DNTH's competition here
ABUS vs VCYT Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, VCYT has a market cap of 3.6B. Regarding current trading prices, ABUS is priced at $4.35, while VCYT trades at $45.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas VCYT's P/E ratio is 41.69. In terms of profitability, ABUS's ROE is +1.29%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, ABUS is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check VCYT's competition here
ABUS vs VKTX Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, VKTX has a market cap of 3.6B. Regarding current trading prices, ABUS is priced at $4.35, while VKTX trades at $30.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas VKTX's P/E ratio is -7.44. In terms of profitability, ABUS's ROE is +1.29%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, ABUS is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check VKTX's competition here
ABUS vs SWTX Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, ABUS is priced at $4.35, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas SWTX's P/E ratio is -13.78. In terms of profitability, ABUS's ROE is +1.29%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, ABUS is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check SWTX's competition here
ABUS vs EWTX Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, EWTX has a market cap of 3.5B. Regarding current trading prices, ABUS is priced at $4.35, while EWTX trades at $32.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas EWTX's P/E ratio is -19.70. In terms of profitability, ABUS's ROE is +1.29%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, ABUS is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check EWTX's competition here
ABUS vs ERAS Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, ERAS has a market cap of 3.5B. Regarding current trading prices, ABUS is priced at $4.35, while ERAS trades at $11.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas ERAS's P/E ratio is -12.09. In terms of profitability, ABUS's ROE is +1.29%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, ABUS is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for ABUS.Check ERAS's competition here
ABUS vs TLX Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, TLX has a market cap of 3.2B. Regarding current trading prices, ABUS is priced at $4.35, while TLX trades at $9.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas TLX's P/E ratio is -473.94. In terms of profitability, ABUS's ROE is +1.29%, compared to TLX's ROE of -0.02%. Regarding short-term risk, ABUS is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for ABUS.Check TLX's competition here
ABUS vs DNLI Comparison May 2026
ABUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABUS stands at 859.3M. In comparison, DNLI has a market cap of 3B. Regarding current trading prices, ABUS is priced at $4.35, while DNLI trades at $18.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABUS currently has a P/E ratio of 5.24, whereas DNLI's P/E ratio is -6.47. In terms of profitability, ABUS's ROE is +1.29%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, ABUS is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for ABUS.Check DNLI's competition here